Finance

Lists
Why is HUMA up 3,70%?
Dive Deeper
HUMA:NASDAQ
Humacyte Inc
0,52 $
+3,70%
(+0,019) 1D
0,52 $
-0,06% (-0,00030)
After hours
Closed: 2 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUMA...
Open
0,51 $
High
0,53 $
Low
0,50 $
Mkt. cap
145,71 млн
Avg. vol.
4,84 млн
Volume
5,34 млн
52-wk high
2,55 $
52-wk low
0,50 $
EPS
-0,49 $
Beta
2,44
Shares outstanding
277,80 млн
No. of employees
184
Open
0,51 $
High
0,53 $
Low
0,50 $
Mkt. cap
145,71 млн
Avg. vol.
4,84 млн
Volume
5,34 млн
52-wk high
2,55 $
52-wk low
0,50 $
EPS
-0,49 $
Beta
2,44
Shares outstanding
277,80 млн
No. of employees
184
News stories
From web sources and news partners
About Humacyte Inc
CEOLaura Niklason
Employees184
Founded2004 ж. 01 қаң.
Headquarters-
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to HUMA in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for HUMA in the last 3 months.
Highest
Current 0,52 $
4,00 $ (+667,02%)
Average
2,06 $ (+295,01%)
Lowest
1,00 $ (+91,75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
4,00 $
+667%
09/21/2026
Josh Jennings
TD Cowen
Buy
Maintained
1,25 $
+139,7%
08/19/2026
Allison Bratzel
Piper Sandler
Hold
Maintained
1,00 $
+91,8%
08/17/2026
Ryan Zimmerman
BTIG
Buy
Maintained
2,00 $
+283,5%
07/28/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
2,00 $
+283,5%
06/01/2026
Matt Miksic
Barclays
Buy
Reiterated
1,50 $
+187,6%
05/13/2026
Last report
2026 ж. 12 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,16 $ / -0,10 $
-54,84%miss
Revenue / Est. (USD)
406,00 м. / 1,11 млн
-63,52%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
753,00 м.
467,00 м.
495,00 м.
406,00 м.
Cost of goods sold
17,53 млн
23,69 млн
20,90 млн
19,38 млн
Cost of revenue
17,53 млн
23,69 млн
20,90 млн
19,38 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,61 млн
7,62 млн
7,83 млн
8,03 млн
Operating expense
7,61 млн
7,62 млн
7,83 млн
8,03 млн
Total operating expenses
25,14 млн
31,30 млн
28,73 млн
27,40 млн
Operating income
-24,39 млн
-30,84 млн
-28,24 млн
-27,00 млн
Other non operating income
4,01 млн
20,57 млн
8,52 млн
-5,16 млн
EBT including unusual items
-17,51 млн
-24,80 млн
-17,62 млн
-36,80 млн
EBT excluding unusual items
-22,40 млн
-12,85 млн
-21,65 млн
-34,08 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17,51 млн
-24,80 млн
-17,62 млн
-36,80 млн
Net profit margin
-2 325,37%
-5 311,35%
-3 559,39%
-9 064,53%
Earnings per share
-0,11
-0,13
-0,09
-0,16
Interest and investment income
590,00 м.
503,00 м.
330,00 м.
388,00 м.
Interest expense
-2,61 млн
-3,09 млн
-2,27 млн
-2,32 млн
Net interest expenses
-2,02 млн
-2,59 млн
-1,94 млн
-1,93 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,52 млн
-29,05 млн
-26,44 млн
-25,21 млн
Gain or loss from assets sale
-
5,00 мың
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары